Legend Biotech (LEGN) Common Equity (2019 - 2026)

Legend Biotech (LEGN) has 7 years of Common Equity data on file, last reported at $1.0 billion in Q4 2025.

• Quarterly Common Equity fell 3.7% year-over-year to $1.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 3.7% YoY) and the FY2025 annual result came in at $1.0 billion, down 3.7% from the prior year.
• Common Equity declined to $1.0 billion in Q4 2025, from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.4 billion in Q2 2023 to a low of $206451.0 in Q1 2021.
• A 5-year average of $889.7 million and a median of $1.0 billion in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 358900.44% — and 2024, when it dropped 17.63%.
• Tracing LEGN's Common Equity over 5 years: stood at $765.9 million in 2021, then dropped by 2.82% to $744.3 million in 2022, then soared by 68.12% to $1.3 billion in 2023, then slipped by 16.84% to $1.0 billion in 2024, then declined by 3.7% to $1.0 billion in 2025.
• The last three Common Equity figures came in at $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025), per Business Quant data.